As of 2026-09-22, the EV/EBITDA ratio of Inovio Pharmaceuticals Inc (INO) is -0.86. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. INO's latest enterprise value is 70.49 mil USD. INO's TTM EBITDA according to its financial statements is -81.87 mil USD. Dividing these 2 quantities gives us the above INO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 16.3x - 17.4x | 16.8x |
| Forward P/E multiples | 19.0x - 21.8x | 20.2x |
| Fair Price | (18.54) - (16.97) | (18.05) |
| Upside | -1595.5% - -1468.7% | -1555.8% |
| Date | EV/EBITDA |
| 2026-09-18 | -0.86 |
| 2026-09-17 | -0.83 |
| 2026-09-16 | -0.77 |
| 2026-09-15 | -0.78 |
| 2026-09-14 | -0.80 |
| 2026-09-11 | -0.87 |
| 2026-09-10 | -0.90 |
| 2026-09-09 | -0.94 |
| 2026-09-08 | -1.04 |
| 2026-09-04 | -1.05 |
| 2026-09-03 | -0.98 |
| 2026-09-02 | -0.98 |
| 2026-09-01 | -0.95 |
| 2026-08-31 | -0.89 |
| 2026-08-28 | -0.91 |
| 2026-08-27 | -0.88 |
| 2026-08-26 | -0.92 |
| 2026-08-25 | -0.91 |
| 2026-08-24 | -0.87 |
| 2026-08-21 | -0.80 |
| 2026-08-20 | -0.83 |
| 2026-08-19 | -0.92 |
| 2026-08-18 | -0.82 |
| 2026-08-17 | -0.77 |
| 2026-08-14 | -0.71 |
| 2026-08-13 | -0.52 |
| 2026-08-12 | -0.39 |
| 2026-08-11 | -0.38 |
| 2026-08-10 | -0.35 |
| 2026-08-07 | -0.29 |
| 2026-08-06 | -0.29 |
| 2026-08-05 | -0.30 |
| 2026-08-04 | -0.28 |
| 2026-08-03 | -0.32 |
| 2026-07-31 | -0.30 |
| 2026-07-30 | -0.27 |
| 2026-07-29 | -0.66 |
| 2026-07-28 | -0.65 |
| 2026-07-27 | -0.58 |
| 2026-07-24 | -0.59 |
| 2026-07-23 | -0.64 |
| 2026-07-22 | -0.68 |
| 2026-07-21 | -0.72 |
| 2026-07-20 | -0.71 |
| 2026-07-17 | -0.74 |
| 2026-07-16 | -0.74 |
| 2026-07-15 | -0.79 |
| 2026-07-14 | -0.78 |
| 2026-07-13 | -0.78 |
| 2026-07-10 | -0.80 |